You just read:

Daiichi Sankyo Announces First Patient Enrolled in Phase 3 QuANTUM-First Trial Investigating Quizartinib in Newly-Diagnosed FLT3-ITD+ Acute Myeloid Leukemia

News provided by

Daiichi Sankyo Company, Limited

Oct 11, 2016, 08:00 ET